Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study.

Wang, Chun-Hsiang

Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study. [electronic resource] - Medicine May 2020 - e19907 p. digital

Publication Type: Journal Article; Randomized Controlled Trial

1536-5964

10.1097/MD.0000000000019907 doi


Adult
Alanine Transaminase--blood
Antiviral Agents--administration & dosage
Drug Administration Schedule
Female
Hepatitis B e Antigens--blood
Hepatitis B virus--drug effects
Hepatitis B, Chronic--drug therapy
Humans
Male
Middle Aged
Prospective Studies
Recurrence
Seroconversion--drug effects
Sustained Virologic Response
Tenofovir--administration & dosage
Time Factors